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ABSTRACT
Rationale and objectives Self-reported smoking
underestimates disease risk. Smoking affects DNA
methylation, in particular the cg05575921 site in the
aryl hydrocarbon receptor repressor (AHRR) gene. We
tested the hypothesis that AHRR cg05575921
hypomethylation is associated with risk of smoking-
related morbidity and mortality.
Methods From the Copenhagen City Heart Study
representing the Danish general population, we studied
9234 individuals. Using bisulphite treated leucocyte
DNA, AHRR (cg05575921) methylation was measured.
Rs1051730 (CHRN3A) genotype was used to evaluate
smoking heaviness. Participants were followed for up to
22 years for exacerbations of COPD, event of lung
cancer and all-cause mortality. Six-year lung cancer risk
was calculated according to the Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial
(PLCOM2012).
Measurements and main results AHRR
(cg05575921) hypomethylation was associated with
former and current smoking status, high daily and
cumulative smoking, short time since smoking cessation
(all p values <7×10–31), and the smoking-related
CHRN3A genotype (−0.48% per T-allele, p=0.002). The
multifactorially adjusted HRs for the lowest versus
highest methylation quintiles were 4.58 (95% CI 2.83 to
7.42) for COPD exacerbations, 4.87 (2.31 to 10.3) for
lung cancer and 1.67 (1.48 to 1.88) for all-cause
mortality. Finally, among 2576 high-risk smokers eligible
for lung cancer screening by CT, observed cumulative
incidences of lung cancer after 6 years for individuals in
the lowest and highest methylation quintiles were 3.7%
and 0.0% (p=2×10–7), whereas predicted PLCOM2012
6-year risks were similar (4.3% and 4.4%, p=0.77).
Conclusion AHRR (cg05575921) hypomethylation, a
marker of smoking behaviour, provides potentially
clinical relevant predictions of future smoking-related
morbidity and mortality.
INTRODUCTION
Tobacco smoking causes morbidity leading to dis-
abilities and reduced life quality, and causes 12% of
all deaths globally.1 Self-reported smoking informa-
tion is subject to recall bias and understatement by
the patient.2 3 Furthermore, it does not capture
subtle, but important variation in smoking behav-
iour due to variation of number of inhalations per
cigarette, depth of inhalations, respiratory retention
of the smoke and heaviness of second-hand on top
of ﬁrst-hand smoking.4 5 Therefore, self-reported
cross-sectional smoking information produces
underestimated risk estimates, as suggested in
genetic studies using a smoking-related genotype of
nicotinic acetylcholine receptor (CHRNA3) as
proxy for the lifetime exposure to tobacco smoke6;
however, in that study, association of genotype with
cigarette consumption was based on current
smoking status and not on lifetime exposure and
was not adjusted for factors that inﬂuence nicotine
metabolism.
Objective measures of smoking behaviour consist
mainly of measurements in body ﬂuids of cotinine7
or exhaled CO concentration.8 With biological
half-lives below 24 hours, these measurements are,
however, not well-suited to estimate long-term
smoking behaviour.
In CpG sites across the genome, methylation
extent is associated with tobacco smoking.9 Of
these, one situated in intron 3 of the aryl
Key messages
What is the key question?
▸ Is the extent of AHRR cg05575921
hypomethylation in leucocyte DNA associated
with risk of smoking-related morbidity and
mortality? If so, does such hypomethylation
provide information beyond that of
self-reported (subjective) smoking information?
What is the bottom line?
▸ Using DNA blood samples drawn in 1991–1994
from individuals in the Copenhagen City Heart
Study, representing the Danish general
population, we followed 9234 individuals for
COPD exacerbations, lung cancer and all-cause
mortality, and found that AHRR cg05575921
hypomethylation strongly predicted risks, also
after adjustment for self-reported smoking
behaviour at the time of blood draw.
Why read on?
▸ Because tobacco smoking remains an
important cause of preventable morbidity and
mortality, but self-reported smoking behaviour
underestimates disease risk, this novel objective
marker of long-term smoking behaviour could
be of clinical value if included in the risk
calculation algorithms identifying high-risk
smokers for screening or other interventions.
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hydrocarbon receptor repressor (AHRR) gene on chromosome 5
(annotated on the Illumina HumanMethylation450 BeadChip
array as probe cg05575921), showed greatest evidence for dif-
ferent methylation in response to exposure to tobacco smoking,
as found by others,10–15 and in a recent meta-analysis.16 AHRR
(cg05575921) methylation extent is also inversely correlated
with serum cotinine,11 exhaled CO concentration and reverts
after smoking cessation.17
Smoking-responsive DNA methylation changes at other loci
are associated with risk of lung cancer and mortality18 19;
however, it is not known whether variation in AHRR
(cg05575921) methylation extent is associated with risk of
future smoking-related morbidity and mortality among indivi-
duals from the general population, and how useful this associ-
ation might be for (pre-)clinical management of smokers.
Screening with low-dose CT scans reduces lung cancer mortality
among individuals with high a priori risk, but only marginally
among those at lowest risk.20 Therefore, several algorithms,
which include self-reported smoking have recently been devel-
oped to predict smokers’ risk of lung cancer.21 22 Measurement
of AHRR methylation extent might, therefore, provide valuable
information beyond that of existing risk prediction models iden-
tifying individuals eligible for CT scan lung cancer screening,
for example the 6-year predicted risk algorithm (PLCOM2012)
from the Prostate, Lung, Colorectal and Ovarian Cancer
Screening Trial.22
We aimed to test the hypothesis that AHRR (cg05575921)
hypomethylation is associated with the risk of smoking-related
morbidity and mortality in the general population. Using
the published lung cancer risk prediction model,22 the 6-year
lung cancer risk was calculated: we then explored if AHRR
(cg05575921) methylation extent improves lung cancer risk pre-
diction among high-risk smokers, and thus helps to decide who
should be offered lung CT scans.
MATERIALS AND METHODS
Study population
We studied 9234 consecutive individuals with available DNA
from the 1991 to 1994 examination of the Copenhagen City
Heart Study, a prospective study of the general population with
equal emphasis on pulmonary and cardiac diseases (see ﬂow-
chart in online supplementay ﬁgure 1)23 24; 98% were whites of
Danish origin. Copenhagen residents were invited to complete a
questionnaire and undergo a physical examination. All partici-
pants gave written informed consent, and a Danish ethics com-
mittee approved the study (KF100.2039/91). Participants
reported on smoking behaviour, alcohol consumption, occupa-
tional exposure to dust and/or welding fumes, exposure to
passive smoking, education, and familial cases of lung cancer.
The answers were reviewed together with an examiner at the
day of attendance. Height and weight were measured, body
mass index was calculated and blood samples were drawn for
DNA.
Smoking behaviour
At the day of attendance in 1991–1994 when DNA was
sampled, participants were asked whether they were current or
former smokers. If they answered afﬁrmative to either of these
questions, they were asked about their current and former
smoking behaviour, including age of smoking initiation, age of
smoking cessation and number of daily consumed cigarettes,
cheroots, cigars and weekly grams of pipe tobacco. Based on
these answers, participants were categorised as never, former
and current smokers; the two latter groups were deﬁned as
smokers. Also, pack-years corresponding to the consumption of
20 cigarettes or equivalent per day for 1 year was calculated for
smokers. Thus, never, former and current smoking, quantitative
smoking information and smoking history were all recorded
only once, at the 1991–1994 examination.
CHRNA3 genotype
The rs1051730 genotype near the nicotinic acetylcholine recep-
tor gene (CHRNA3) was determined with a Taqman assay as
described earlier.24
Methylation extent
The AHRR cg05575921 methylation extent was measured in
duplicate samples of bisulphite treated DNA from peripheral
blood drawn at the 1991–1994 examination (see online
supplementary appendix). Measurements were adjusted for 13
batches, and the order of individuals examined, sampling and
measurements were according to the day of the month for birth-
day (ie, the 1st–the 31st day of the month) of the individual,
thus presumably random and non-differential to AHRR
cg05575921 methylation extent, or other measured or unmeas-
ured variables. Measurements were validated by Pyrosequencing
as outlined in the online supplementary appendix.
Morbidity and mortality
We selected COPD exacerbations, lung cancer and all-cause
mortality a priori because we expected these to show the stron-
gest association with a potential smoking-related variable. For
COPD exacerbations (ICD8, codes 490-2 until 1993, and
ICD10, J40-4 from 1994 and onwards), dates of hospital diag-
noses with exacerbation were from the national Danish Patient
Registry, from 1977 to April 2013, as done previously.25 For
lung cancer (ICD7, codes 1624 or 4624 until 1977 and ICD10,
code C34 from 1978 and onwards), date was from the national
Danish Cancer Registry from 1943 to December 2012, as done
previously.24 For death or emigration (n=110), information was
from the national Danish Civil Registration System from date of
examination until April 2013.
Lung cancer risk prediction model
Since screening for lung cancer using CT scan reduces lung
cancer mortality,20 risk prediction models to identify individuals
most likely to beneﬁt from lung cancer screening have been
developed: the Prostate, Lung, Colorectal and Ovarian Cancer
Screening Trial22 risk prediction model (PLCOM2012) was calcu-
lated as outlined in the online supplementary appendix.
Statistical analysis
We used STATA V.13.1. All 9234 individuals were categorised
into ranked quintiles of DNA AHRR (cg05575921) methylation
extent, with the quintile with the highest methylation, presum-
ably least exposed to smoking, as the reference group. We
showed data in quintiles for simple illustrative presentation of
the results; however, analyses of methylation extent on a con-
tinuous scale are also shown. We used linear regression,
Cuzick’s extension of the Wilcoxon rank-sum test and Pearson’s
χ2 test.
Follow-up time for each individual began at baseline, which
was deﬁned as date of the 1991–94 examination with DNA
sampling, and ended at date of death, event, emigration, or
December 2012 (lung cancer) or April 2013 (mortality), which-
ever came ﬁrst. For COPD exacerbations, the model allowed for
multiple events for the same individual, while taking into
account that the failure-times within each individual could be
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correlated. Individuals with lung cancer prior to the date of
examination were excluded from analyses of lung cancer.
Minimum, median and maximum follow-up periods were
4 days, 19 years and 22 years for COPD exacerbation, 4 days,
19 years and 21 years for lung cancer and 4 days, 19 years and
22 years for all-cause mortality.
We plotted cumulative incidences, accounting for the compet-
ing risks of death and emigration, similarly,26 and tested differ-
ences between quintiles using Fine–Gray regression or log-rank
trend tests. HRs for morbidity or all-cause mortality with 95%
CIs were calculated using Cox proportional hazards regression.
Time scale was chronological age taking into account that risk
time began at date of the 1991–1994 examination with DNA
sampling. This means that age is automatically adjusted for and
is referred to as ‘age-adjusted’ as further described in the online
supplementary appendix. Corresponding analyses using Fine–
Gray regression with death and emigration as equal competing
events were also conducted as sensitivity analyses. We applied
two models adjusted for sex and age, and multifactorially add-
itionally for the use of alcohol (continuous), body mass index
(continuous), exposure to dust (no/yes), exposure to passive
smoking (no/yes), history of cancer prior to attendance (no/yes),
history of COPD exacerbations prior to attendance (no/yes; for
lung cancer and all-cause mortality), familial history of lung
cancer (no/yes), education level (categorical), smoking status
(never, former current), current and cumulative consumption of
tobacco. Covariates in the multifactorially adjusted models were
included because they are used in the PLCOM2012 prediction
model.22 For simplicity, we used the same model for all three
endpoints. All covariates were recorded once, at the 1991–94
examination. We tested the proportional hazards assumption
using Schoenfeld residuals and no major violations were
observed. For further information on the statistical modelling,
please see the online supplementary appendix.
We chose not to adjust p values for multiple comparisons. If
we consider association analyses for two morbidity endpoints,
and one mortality endpoint, Bonferroni correction for multiple
comparisons would require p values <0.017 (0.05/3=0.017).
However, as most p values reported are much below, adjustment
for multiple comparisons would not affect the main conclusions
of the present paper.
RESULTS
Median of AHRR (cg05575921) methylation extent among
9234 individuals was 56% (IQR, 50–63%). Ranked quintiles of
AHRR (cg05575921) methylation extent were associated with
all baseline characteristics at the time blood collection for DNA
extraction, except personal history of cancer (table 1). To valid-
ate our Taqman assay, we also measured methylation extent in
170 individuals using Pyrosequencing at the AHRR
(cg05575921) site, and the results from the two assays were
strongly associated (R2=0.70, F=381, p<0.0001), comparable
to other studies of two methylation measurement techniques.27
Overlap of morbidity and mortality, among all, and stratiﬁed by
smoking status are given in online supplementary ﬁgure 2.
Smoking behaviour
The proportion of smokers was higher among men than among
women (p=3×10−39, see online supplementary table S1), as
expected. For both former and current smokers, ranked
quintiles of lower cg05575921 methylation extent were
associated with higher daily tobacco consumption (p=1×10−41
and 2×10−63), higher cumulative tobacco consumption
(p=3×10−63 and 2×10−35), longer smoking duration
(p=8×10−71 and p=4×10−7), and with shorter time since ces-
sation (former smokers only: p=1×10−43); corresponding
results for methylation extent on a continuous scale were similar
(ﬁgure 1). Cumulative tobacco consumption in former smokers
increased more steeply in men than in women across ranked
quintiles of lower AHRR (cg05575921) methylation extent
(p=0.002, interaction test). Median AHRR (cg05575921)
methylation extent was 64% among never smokers, 60%
Table 1 Baseline characteristics of 9234 participants from the Copenhagen City Heart Study
Leucocyte DNA methylation of cg05575921, quintiles
All 1st (highest) 2nd 3rd 4th 5th (lowest) p Value*
Number 9234 1754 1783 1815 1862 2020 –
AHRR (cg05575921) methylation
extent, %
56 (50–63) 68 (65–71) 62 (60–63) 56 (54–58) 51 (49–53) 46 (44–48) –
Women, n (%) 5114 (55) 1196 (68) 1086 (61) 935 (52) 909 (49) 988 (49) 1×10−45
Age, years 60 (47–70) 59 (45–71) 62 (45–73) 62 (49–72) 60 (50–69) 59 (47–67) 0.0004
Education below 10 years, n (%) 5141 (56) 826 (47) 900 (50) 991 (55) 1158 (62) 1266 (63) 3×10−30
Body mass index, kg/m2 25 (22–28) 25 (23–28) 25 (23–28) 25 (23–28) 25 (22–28) 24 (22–27) 2×10−18
Registered COPD, n (%) 152 (1.7) 12 (0.7) 15 (0.8) 30 (1.7) 38 (2.0) 57 (2.8) 3×10−7
FEV1/FVC ratio <Lower limit of
normal, n (%)
1445 (16) 106 (6) 116 (7) 261 (15) 440 (24) 522 (26) 4×10−104
Personal history of cancer, n (%) 458 (5) 89 (5) 97 (5) 86 (5) 94 (5) 92 (5) 0.76
Family history of lung cancer, n (%) 855 (9) 157 (9) 139 (8) 164 (9) 168 (9) 227 (11) 0.006
Ever smokers, n (%) 7120 (77) 796 (45) 1029 (58) 1493 (82) 1802 (97) 2000 (99) <10−300
Alcohol, g/week 60 (12–156) 48 (12–108) 48 (12–120) 72 (12–156) 72 (24–180) 84 (24–192) 1×10−34
Occupational exposure to dust or
fumes, n (%)
1713 (19) 211 (12) 239 (13) 314 (17) 438 (24) 511 (25) 1×10−36
Exposure to passive smoking, n (%) 3321 (36) 458 (26) 480 (27) 600 (33) 809 (44) 974 (48) 3×10−68
Predicted 6-year lung cancer
risk†, %
0.69 (0.11–2.26) 0.05 (9×10−4–0.42) 0.16 (0.01–0.86) 0.55 (0.09–2.04) 1.14 (0.30–2.83) 1.26 (0.36–3.09) <10−300
Values are median (IQR) for continuous variables and frequencies for categorical variables.
*p Values were calculated with Cuzick’s extension of the Wilcoxon rank-sum test (age, alcohol and predicted lung cancer risk) or Pearson’s χ2-test (categorical variables).
†As defined in NEJM 2013;368:728–36. Smokers only.
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among former smokers and 50% among current smokers
(p<1×10−300, see online supplementary table S1). Among
never smokers, AHRR (cg05575921) methylation extent was
similar in those exposed to (n=512) and not exposed to
(n=1575) passive smoking (65% and 64%, p=0.95).
The rs1051730 genotype near the nicotinic acetylcholine
receptor gene (CHRNA3) is a likely causal genetic marker of the
heaviness of smoking, with the T allele associated with increased
consumption of tobacco.24 We, therefore, tested whether this
genotype also was associated with the objectively measured
AHRR (cg05575921) methylation extent: methylation extent
declined by 0.67% (95% CI 0.39% to 0.97%) per T allele
(p=5×10−6) among current smokers, and by 0.48% (0.18% to
0.78%, p=0.002) among all smokers (see online supplementary
ﬁgure 3). These associations remained after adjustments for self-
reported smoking, but was absent among never smokers
(p=0.96, not shown).
Morbidity
For COPD exacerbation, we followed all individuals from time
of examination, and during 143 000 person-years we detected
5261 events of COPD exacerbations among 1309 individuals.
Among former and current smokers, there was an association
between ranked quintiles of lower AHRR (cg05575921)
methylation extent with higher incidence of COPD exacerba-
tion (p=7×10−7 and p=1×10−4, Fine and Gray trend test)
(ﬁgure 2, upper panels). The HRs for COPD exacerbation for
individuals in the 5th versus 1st quintile of methylation extent
among never, former and current smokers combined were 13.2
(95% CI 8.79 to 19.7) in the age and sex adjusted model, and
4.58 (2.83 to 7.42) in the multifactorially adjusted model
(ﬁgure 3).
For lung cancer, we followed 9211 individuals without lung
cancer at the time of examination, and during 141 000 person-
years we detected 352 individuals with lung cancer. Among
former and current smokers, there was an association across
ranked quintiles of lower AHRR (cg05575921) methylation
extent with higher incidence of lung cancer (p=3×10−11 and
p=1×10−7, log-rank trend test), whereas this was not seen
among never smokers (ﬁgure 2 middle panels). The HRs for
lung cancer for individuals in the 5th versus 1st quintile of
methylation extent among never, former and current smokers
combined were 18.2 (95% CI 9.25 to 35.6) in the age and
sex adjusted model, and 4.87 (2.31 to 10.3) in the multifacto-
rially adjusted model (ﬁgure 3). Risk estimates were slightly atte-
nuated when taking competing risk of death and emigration
into consideration (compare ﬁgure 3 with online supplementary
ﬁgure 4).
Figure 1 Smoking behaviour as a function of AHRR (cg05575921) methylation extent, among former and current smokers. The lower number of
individuals, for smoking history compared with tobacco consumption, is explained by missing information on smoking history. Bar values are means
and SEs. Estimates (95% CI) and p values per lower quintile and per 10% lower methylation extent were calculated with unadjusted linear
regression. p Values for sex interaction were from a likelihood ratio test that compared the main effects in a linear regression model to a model also
including a two-factor (sex by quintile of methylation extent) interaction term. AHRR, aryl hydrocarbon receptor repressor.
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Mortality
For all-cause mortality, 4396 individuals died during 143 000
person-years. Among former and current smokers, there was
an association across ranked quintiles of lower AHRR
(cg05575921) methylation extent with higher all-cause mortal-
ity (p=4×10−17 and p=9×10−22, log-rank trend test). In
current smokers, the difference of median age at death between
individuals in the 1st and 5th methylation extent quintile was
8.5 years (not shown) (ﬁgure 2 lower panels). The HRs for all-
cause mortality for individuals in the 5th versus 1st quintile of
methylation extent among never, former and current smokers
combined were 2.42 (95% CI 2.19 to 2.66) in the age and sex
adjusted model, and 1.67 (1.48 to 1.88) in the multifactorially
adjusted model (ﬁgure 3).
Prediction of lung cancer risk
Among high-risk smokers (n=2576) eligible for lung cancer
screening by CT scan due to a PLCOM2012
22 lung cancer 6-year
risk above 1.3455% (see online supplementary ﬁgure 5), the
observed cumulative incidence of lung cancer after 6 years for
individuals in the 5th and 1st quintile of methylation extent
were 3.7% and 0.0% (p=2×10−7, log-rank trend test across all
quintiles, ﬁgure 4), whereas the predicted PLCOM2012 lung
cancer 6-year risks were similar (4.3% and 4.4%, p=0.77 trend
test). The 6-year follow-up was chosen, since it was used in the
publication where the prediction model was developed.22 After
more than 20 years of follow-up, no smoker in the highest quin-
tile of AHRR (cg05575921) methylation extent developed lung
cancer (see online supplementary ﬁgure 6); however, this group
had a relatively low number of individuals. Prediction of lung
cancer risk with receiver operating characteristic (ROC) statistics
for AHRR (cg05575921) methylation extent and the PLCOM2012
risk estimate produced similar area under curve (AUC) estimates
in all 7120 ever smokers (p=0.11 for difference), but an AUC of
61% for AHRR (cg05575921) methylation extent versus 51%
for the PLCOM2012 risk estimate in 2576 high-risk smokers
(p=0.0001 for difference) (see online supplementary ﬁgure 7).
DISCUSSION
Among 9234 individuals from the general population, AHRR
(cg05575921) methylation extent was lower among smokers
than non-smokers, and inversely correlated with smoking inten-
sity, in accordance with previous ﬁndings.9–15 28 AHRR
(cg05575921) hypomethylation was predictive of high risk of
COPD exacerbation, lung cancer and all-cause mortality, also
after adjustment for past and current smoking behaviour. Within
Figure 2 Cumulative incidences of COPD exacerbations, lung cancer and all-cause mortality as a function of ranked AHRR (cg05575921)
methylation extent quintiles, among never, former and current smokers. Cumulative incidences were calculated by the Fine and Gray method, taking
death and emigration as competing events into consideration, except for all-cause mortality for which only emigration was a competing event. For
COPD exacerbations, the trend test is from the Fine and Gray regression instead of the log-rank trend test because the model allowed for multiple
events for the same individual. Never smokers in 5th quintile were excluded due to very low numbers. AHRR, aryl hydrocarbon receptor repressor.
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Figure 3 HRs of COPD exacerbation, lung cancer and all-cause mortality by AHRR (cg05575921) methylation extent quintiles and per 10% lower
extent, among never, former and current smokers using a Cox regression model. Multifactorial adjustment was for age, sex, use of alcohol
(continuous), body mass index (continuous), exposure to dust (no/yes), exposure to passive smoking (no/yes), history of cancer prior to attendance
(no/yes), history of COPD prior to attendance (no/yes; for lung cancer and all-cause mortality), familial history of lung cancer (no/yes), education
level (categorical), smoking status (never, former current), current and cumulative consumption of tobacco. p Values for trend were from the Cox
regression model, where quintiles were inserted as a continuous variable. p Values (continuous) for the HR per 10% decrease of methylation extent
are also shown. AHRR, aryl hydrocarbon receptor repressor.
Figure 4 Cumulative incidence of lung cancer among 2576 high-risk smokers, and observed and predicted 6-year risk by AHRR (cg05575921)
methylation extent quintiles. High risk was deﬁned as predicted PLCOM2012 6-year risk>1.3455%.
22 AHRR, aryl hydrocarbon receptor repressor;
PLCOM2012, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
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a large group of smokers with a 6-year a priori risk of lung
cancer above the current cut-off for lung CT scan, AHRR
cg05575921 methylation extent separated individuals into a
very low, an intermediate and a high-risk group. This is a novel
ﬁnding.
AHRR (cg05575921) methylation extent was an accurate
marker of several components of the smoking history. AHRR
expression is induced by polycyclic aromatic hydrocarbons29
and cg05575921 methylation marks an upregulation of the
expression of AHRR in blood cells30 and lung tissue.12 Whether
cg05575921 hypomethylation of leucocyte DNA in itself has
any direct causal role in the development of smoking-related
diseases is not known. Observational studies such as ours cannot
clarify this, but the AHRR protein is located in the cell
nucleus,29 and silencing of AHRR enhances tumour growth
pleiotropically through increased Aryl Hydrocarbon Receptor
activity.31
Cg05575921 methylation extent varied with smoking behav-
iour, even among former smokers, who had quit many years
before blood sampling, which leads to different exposure to
toxic effects of smoking. This suggests that AHRR cg05575921
methylation extent is less dynamic in adults than in new-borns,
where more rapid attenuation of hypomethylation is seen once
the antenatal exposure is removed.32 A small number of never
smokers have low AHRR (cg05575921) methylation extent, pre-
sumably due to environmental exposures and may have
increased risk of lung cancer.
Three observations support the notion that measurement of
AHRR (cg05575921) methylation extent is superior to self-
reported smoking behaviour when assessing an individual’s risk
of smoking-related morbidity and mortality. First, AHRR
(cg05575921) methylation extent was associated with the
rs1051730 genotype of the nicotinic acetylcholine receptor
gene (CHRNA3), a variant associated with increased smoking
behaviour,6 also after adjustments for self-reported smoking.
This suggests that AHRR (cg05575921) methylation extent is
superior at capturing individuals’ ‘true’ smoking behaviour.
Second, risk estimates of future smoking-related morbidity by
methylation extent remained high even after adjustments for
self-reported smoking. Third, about 70% of the lung cancer
burden is attributed to smoking alone1 and in ROC statistics of
incident lung cancer in all smokers, AHRR (cg05575921)
methylation extent performed similarly to the PLCOM2012 pre-
diction model, which includes information on present and
former smoking behaviour. Among high-risk smokers, the rela-
tively bad performance of PLCOM2012 prediction model might
be due to the fact that it was developed to produce a binary risk
cut-off for lung CT scan in smokers and not to be used as a
continuous risk variable.
If AHRR (cg05575921) methylation extent is indeed a better
indicator of the harmful effects of smoking than self-reported
smoking behaviour, this points towards the potential clinical use
of AHRR (cg05575921) methylation extent in stratifying
smokers into different risk groups prior to lung CT scan. For
this purpose, the relatively stable AHRR (cg05575921) methyla-
tion extent could in the future be supplemented with short-term
objective epigenetic markers of smoking behaviour. It could
seem risky to base a decision on lung CT scan on a single blood
test sampled years previously, and linked to smoking at the time
of sampling, to predict the individual’s lung cancer risk. Similar
arguments are also valid for the PLCOM2012 prediction model
used to select for lung CT scan. While AHRR (cg05575921)
methylation extent and the PLCOM2012 prediction model only
predict what will happen for the average person, predictions are
naturally not exact for a speciﬁc individual.
Strengths of this study include the large number of general
population individuals followed for more than 20 years without
losses to follow-up. The Danish health registers allowed us to
examine associations with three endpoints and this combined
with the high frequency and heaviness of tobacco smoking in
Denmark in the 1990s gave us adequate power to test the
hypotheses.
Some limitations must, however, be acknowledged. This is the
ﬁrst large-scale application of a simple assay quantifying DNA
methylation; however, two arguments support the notion that
the assay captured relevant information. First, the measurements
correlated with results from Pyrosequencing. Second, we could
reproduce the expected association with the smoking-related
CHRN3A genotype.
Also, COPD exacerbation during follow-up was only deﬁned
by diagnostic codes for hospital admissions, and not additionally
by glucocorticosteroide and/or antibiotic treatment. We also
lacked information on other variables, which may impact
methylation, for example exposure to benzene, lead and
arsenic.33 An invalid, non-differential measurement technique
would only tend to pull associations with phenotypes, morbidity
and mortality towards the null hypothesis, and thus cannot
explain our positive ﬁndings.
Misclassiﬁcation of diagnoses from the Danish registries is a
potential limitation, but is likely non-differential by methylation
extent and can therefore not explain our results on COPD.
Importantly, for lung cancer, diagnoses are based on histological
conﬁrmation by a fully trained pathologist and registration is
compulsory by law. For all-cause mortality, there is no misclassi-
ﬁcation in Denmark.
The 9234 individuals examined only represent 56% of the
invited population. Thus, smoking-related death or severe
disease may have prevented some from being examined.
However, this potential self-selection of healthy individuals
cannot explain our positive ﬁndings of associations with self-
reported smoking, morbidity and mortality. Importantly, we
detected the presumed unbiased association with the genotype
of the smoking-related CHRN3A genotype, for example the
genotype distributions among ever and never smokers were
similar (p=0.24, χ2 test; data not shown), suggesting that if
present, selection might be of minor importance. Furthermore,
we only measured AHRR (cg05575921) methylation extent
once, precluding adjustment for within-person variation, regres-
sion dilution bias and determination of the natural pattern of
methylation after smoking cessation. Nevertheless, we did
detect an association of ranked AHRR (cg05575921) methyla-
tion quintiles with time since cessation.
It could be argued that independent validation of our ﬁndings
would be preferable; however, the strengths and magnitudes of
the associations, and the biological plausibility involving a well-
known disease causing lifestyle, argue against the possibility that
the ﬁndings are due to chance alone.
In conclusion, we found that AHRR (cg05575921) hypo-
methylation was associated with smoking, high smoking-related
morbidity and with high all-cause mortality. Among smokers at
high risk of lung cancer, and eligible to screening with CT scan,
AHRR (cg05575921) methylation extent could help to identify
a subgroup with the potential most beneﬁt from a lung CT scan.
Cost–beneﬁt analyses of adding AHRR (cg05575921) methyla-
tion extent to selection for lung CT scan should be explored in
future studies.
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